Drugs / VONLEROLIZUMAB
VONLEROLIZUMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02410512 | Apr 2015 → Nov 2019 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02219724 | Aug 2014 → Jul 2017 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03029832 | Apr 2017 → Apr 2018 | urothelial carcinoma | Genentech, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-05-02 | Genentech, Inc. | Results Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting gene.com ↗
Early results for atezolizumab in combination with targeted medicines and the investigational cancer immunotherapy MOXR0916, an OX40 agonist |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-05-02 | Genentech, Inc. | Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting gene.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VONLEROLIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990022 ↗ |
| Known as | MOXR0916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02410512 ↗ |
| Known as | Pogalizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990022 ↗ |
| Known as | R0-7021608 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990022 ↗ |
| Known as | RG-7888 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990022 ↗ |
| Known as | RO7021608 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990022 ↗ |
| Action | Activate | “humanized agonist anti-OX40 monoclonal antibody” NCT02410512 ↗ |
| Modality | Monoclonal antibody | “humanized agonist anti-OX40 monoclonal antibody” NCT02410512 ↗ |
| Route | Intravenous | “administered as intravenous infusion” NCT02219724 ↗ |